SGMA reports year-over-year growth in Q3 earnings driven by cost cuts and a one-time gain despite a 26% revenue decline. Management expects revenue to...

Enzo Biochem revenues decline in second-quarter fiscal 2025. Cost cuts improve margins, but NYSE compliance issues and market slowdown persist.

VALU's fiscal Q3 earnings per share decline year over year as rising costs pressure margins, while higher income from EAM helps offset weaker...

Kewaunee Scientific's revenues rise 43.6% in Q3, but profits decline due to higher expenses and Nu Aire acquisition costs. Backlog hits $221.6...

Kewaunee Scientific's revenues rise 43.6% in Q3, but profits decline due to higher expenses and Nu Aire acquisition costs. Backlog hits $221.6...

CTAS' third-quarter fiscal 2025 organic revenues increase 8.4% year over year on solid segmental sales.

CTAS' third-quarter fiscal 2025 organic revenues increase 8.4% year over year on solid segmental sales.

JBL reports a top-line decline year over year, owing to weakness in renewable energy and EV verticals. Healthy demand in AI native cloud and data...

JBL reports a top-line decline year over year, owing to weakness in renewable energy and EV verticals. Healthy demand in AI native cloud and data...

FDX' third-quarter fiscal 2025 earnings and revenues improve year over year.